Tempus AI, Inc. (NASDAQ:TEM) Director Theodore Leonsis Sells 205,847 Shares

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) Director Theodore Leonsis sold 205,847 shares of the business's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $67.66, for a total transaction of $13,927,608.02. Following the completion of the sale, the director now owns 15,511 shares in the company, valued at $1,049,474.26. This represents a 92.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Tempus AI Trading Up 1.0%

TEM stock traded up $0.72 during midday trading on Monday, reaching $72.00. 10,143,070 shares of the company's stock traded hands, compared to its average volume of 7,017,628. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The business has a 50-day moving average price of $56.60 and a two-hundred day moving average price of $52.38. The company has a market capitalization of $12.46 billion and a P/E ratio of -9.23.

Tempus AI (NASDAQ:TEM - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. The business had revenue of $255.74 million during the quarter, compared to analyst estimates of $248.13 million. Tempus AI's quarterly revenue was up 75.4% compared to the same quarter last year. Equities research analysts forecast that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. William Blair reiterated a "market perform" rating on shares of Tempus AI in a research report on Tuesday, February 25th. Piper Sandler boosted their price objective on shares of Tempus AI from $55.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, May 15th. Needham & Company LLC reiterated a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a research report on Wednesday, May 7th. Bank of America upped their target price on shares of Tempus AI from $48.00 to $68.00 and gave the company a "neutral" rating in a report on Tuesday, May 20th. Finally, Morgan Stanley upped their target price on shares of Tempus AI from $60.00 to $65.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $63.42.

Institutional Trading of Tempus AI

Hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. bought a new stake in shares of Tempus AI in the fourth quarter worth $216,000. Wells Fargo & Company MN increased its stake in shares of Tempus AI by 13.2% in the fourth quarter. Wells Fargo & Company MN now owns 2,384 shares of the company's stock worth $80,000 after buying an additional 278 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Tempus AI in the fourth quarter worth $178,000. SeaCrest Wealth Management LLC bought a new stake in shares of Tempus AI in the first quarter worth $535,000. Finally, ProShare Advisors LLC bought a new stake in shares of Tempus AI in the fourth quarter worth $244,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.